Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
RUT
Market Cap
1.69B
Enterprise Value
1.77B
Income
-7.60M
Sales
398.74M
Book/sh
6.41
Cash/sh
1.41
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
1576
IPO
Dec 11, 2020
P/E
-
Forward P/E
27.94
PEG
22.00
P/S
4.23
P/B
1.73
P/C
7.85
P/FCF
21.57
EV/EBITDA
20.03
EV/Sales
4.45
Quick Ratio
2.58
Current Ratio
2.58
Debt/Eq
0.31
LT Debt/Eq
0.30
Option/Short
Yes / Yes
EPS (ttm)
-0.05
EPS next Y
0.40
EPS next Q
0.10
EPS this Y
-24.02%
EPS next Y
18.42%
EPS next 5Y
1.27%
EPS past 3/5Y
- 50.19%
Sales past 3/5Y
7.66% 11.45%
EPS Y/Y TTM
-169.67%
Sales Y/Y TTM
-4.05%
EPS Q/Q
-317.89%
Sales Q/Q
-9.29%
Insider Own
36.33%
Insider Trans
0.00%
Inst Own
80.21%
Inst Trans
-4.58%
ROA
-1.65%
ROE
-2.38%
ROIC
-0.60%
Gross Margin
49.87%
Oper. Margin
4.44%
Profit Margin
-1.91%
SMA20
-1.58%
SMA50
12.47%
SMA200
49.60%
Trades
Shs Outstand
152.54M
Shs Float
97.13M
52W High
12.61 -12.29%
52W Low
4.45 148.54%
Volatility
4.96% 5.66%
ATR (14)
0.58
RSI (14)
52.54
Beta
1.23
Rel Volume
0.00
Avg Volume
2.61M
Volume
0
Perf Week
-8.78%
Perf Month
17.04%
Perf Quarter
32.30%
Perf Half Y
140.96%
Perf YTD
25.54%
Perf Year
35.37%
Perf 3Y
-24.30%
Perf 5Y
-69.29%
Perf 10Y
-
Prev Close
11.06
Price
11.06
Change %
0.00%
Consensus
Buy
Avg. Price Target
$12.68
Implied Upside
+14.6%
Analysts14incl. previous ratings
Rating Distribution6 Buy · 8 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Mar 06, 2026Downgrade
BCS logoBBarclays
Overweight → Equal Weight$8-27.7%
Feb 27, 2026Downgrade
CCraig Hallum
Buy → Hold$10-9.6%
Jan 06, 2026Upgrade
LLeerink Partners
Market Perform → Outperform$13+17.5%
Nov 21, 2025Initiated
RRothschild & Co Redburn
Buy$10-9.6%
Nov 13, 2025Initiated
BMO logoBBMO Capital Markets
Market Perform$9-18.6%
Sep 29, 2025Initiated
CCraig Hallum
Buy$16+44.7%
Jul 03, 2025Resumed
MS logoMMorgan Stanley
Equal-Weight$16+44.7%
May 08, 2025Upgrade
BCS logoBBarclays
Equal Weight → Overweight$14+26.6%
Feb 27, 2025Initiated
TD logoTTD Cowen
Buy$16+44.7%
Sep 27, 2024Upgrade
UBS logoUUBS
Neutral → Buy$16+44.7%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pedersen Leif EOfficerSep 03 '26Proposed Sale8.3236,066300,069Sep 03 11:09 AM
Anhalt RonaChief Human Resources OfficerJun 01 '26Option Exercise0.007,147019,030Jun 02 05:15 PM
Corcoran DanielSVP and General CounselJun 01 '26Option Exercise0.0022,830039,939Jun 02 05:14 PM
Collins CynthiaDirectorMay 14 '26Option Exercise0.0015,757051,846May 15 04:31 PM
Reynders John V WChief Financial OfficerMay 14 '26Option Exercise0.0015,757026,466May 15 04:29 PM
BROSHY ERANChairmanMay 14 '26Option Exercise0.0015,757050,708May 15 04:28 PM
Bedi ArjunDirectorMay 14 '26Option Exercise0.005,54705,547May 15 04:28 PM
CASHMAN JAMES E IIIChairmanMay 14 '26Option Exercise0.0015,7570484,197May 15 04:27 PM
Killefer NancyDirectorMay 14 '26Option Exercise0.0015,757051,846May 15 04:26 PM
Crane Rosemary ADirectorMay 14 '26Option Exercise0.0015,757045,672May 15 04:26 PM
WALSH MATTHEW MDirectorMay 14 '26Option Exercise0.0015,7570213,316May 15 04:25 PM
Resnick Jon MatthewChief Executive OfficerMay 11 '26Option Exercise0.0059,766059,766May 13 04:53 PM
Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFFApr 01 '26Option Exercise0.0033,1670113,744Apr 03 04:11 PM
McKemey AdrianPresident, Drug Dev. SolutionsApr 01 '26Option Exercise0.0010,849010,849Apr 03 04:10 PM
Corcoran DanielSVP and General CounselApr 01 '26Option Exercise0.0010,849027,070Apr 03 04:09 PM
Gallagher John EChief Financial OfficerApr 01 '26Option Exercise0.0050,6050103,174Apr 03 04:07 PM
Aspbury RobertPRESIDENT, PREDICTIVE TECHApr 01 '26Option Exercise0.0033,1670339,581Apr 03 04:06 PM
Anhalt RonaChief Human Resources OfficerApr 01 '26Option Exercise0.009,764014,945Apr 03 04:04 PM
Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017 and is headquartered in Radnor, PA.
Senior AdvisorMr. Leif E. Pedersen
CEO & DirectorMr. Jon Resnick
President & Chief Commercial OfficerMr. Julien Perrier
Interim CFOMr. Faiz Mohammed
Chief Technology Officer & Chief AI OfficerDr. Christopher Bouton Ph.D.